Effector TH17 Cells Give Rise to Long-Lived TRM Cells that Are Essential for an Immediate Response against Bacterial Infection

Publication date: 22 August 2019Source: Cell, Volume 178, Issue 5Author(s): Maria Carolina Amezcua Vesely, Paris Pallis, Piotr Bielecki, Jun Siong Low, Jun Zhao, Christian C.D. Harman, Lina Kroehling, Ruaidhrí Jackson, Will Bailis, Paula Licona-Limón, Hao Xu, Norifumi Iijima, Padmini S. Pillai, Daniel H. Kaplan, Casey T. Weaver, Yuval Kluger, Monika S. Kowalczyk, Akiko Iwasaki, Joao P. Pereira, Enric EspluguesSummaryAdaptive immunity provides life-long protection by generating central and effector memory T cells and the most recently described tissue resident memory T (TRM) cells. However, the cellular origin of CD4 TRM cells and their contribution to host defense remain elusive. Using IL-17A tracking-fate mouse models, we found that a significant fraction of lung CD4 TRM cells derive from IL-17A-producing effector (TH17) cells following immunization with heat-killed Klebsiella pneumonia (Kp). These exTH17 TRM cells are maintained in the lung by IL-7, produced by lymphatic endothelial cells. During a memory response, neither antibodies, γδ T cells, nor circulatory T cells are sufficient for the rapid host defense required to eliminate Kp. Conversely, using parabiosis and depletion studies, we demonstrated that exTH17 TRM cells play an important role in bacterial clearance. Thus, we delineate the origin and function of airway CD4 TRM cells during bacterial infection, offering novel strategies for targeted vaccine design.G...
Source: Cell - Category: Cytology Source Type: research

Related Links:

Conclusions: The PHiD-CV vaccination program in Brazil has resulted in important reductions of pneumococcal disease and substantial cost savings. Instead of switching PCVs, expanding vaccine coverage or investing in other health care interventions would be a more efficient use of resources to improve the health of the population in Brazil.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Vaccine Reports Source Type: research
Publication date: 2019Source: Advances in Virus Research, Volume 105Author(s): M. Alejandra Tortorici, David VeeslerAbstractCoronaviruses (CoVs) have caused outbreaks of deadly pneumonia in humans since the beginning of the 21st century. The severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 and was responsible for an epidemic that spread to five continents with a fatality rate of 10% before being contained in 2003 (with additional cases reported in 2004). The Middle-East respiratory syndrome coronavirus (MERS-CoV) emerged in the Arabian Peninsula in 2012 and has caused recurrent outbreaks in humans w...
Source: Advances in Virus Research - Category: Virology Source Type: research
Mycoplasma bovis is an important pathogen of cattle causing bovine mycoplasmosis. Clinical manifestations are numerous, but pneumonia, mastitis, and arthritis cases are mainly reported. Currently, no efficient vaccine is available and antibiotic treatments are not always satisfactory. The design of new, efficient prophylactic and therapeutic approaches requires a better understanding of the molecular mechanisms responsible for M. bovis pathogenicity. Random transposon mutagenesis has been widely used in Mycoplasma species to identify potential gene functions. Such an approach can also be used to screen genomes and search f...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia;   Respiratory Tract Diseases;   Respiratory Tract Infections Interventions:   Biological: Protein based pneumococcal vaccine(Low dose);   Biological: Protein based pneumococcal vaccine placebo(Low dose);   Biological: Protein based pneumococcal vaccine(Middle dose);   Biological: Protein based pneumococcal vaccine placebo(Middle dose);   Biological: Protein based pneu mococcal vaccine(High dose);   Biological: Protein based pneumococcal vaccine placebo(High dose) Sponsors:   CanSino Biologics Inc.;   Henan Cen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cytology | Pneomococcal Vaccine | Pneumonia | Study | Vaccines